Low-cost B-cell depleting therapy is as effective as standard treatment for multiple sclerosis
A Norwegian Swedish clinical trial published in the New England Journal of Medicine (NEJM) demonstrates that rituximab, a…
BioInvent’s BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC (EHA 2026)
BioInvent will host an in-person KOL lunch briefing (11:45 a.m. – 2:00 p.m. CEST / 5:45 – 8:00…
Early glucocorticoid tapering reduces damage in vasculitis maintenance therapy
Glucocorticoids are the cornerstone of initial vasculitis treatment, used to rapidly control inflammation and protect vital organs. EULAR –…
Money Talks in Hospitals’ Adoption of Oncology Biosimilars
Hospitals’ use of biosimilars for three major oncology drugs increased from 18-37% in 2020 to 84-93% in 2024.Hospitals’…
Early immunotherapy shows promise for treating anti-IgLON5 disease
Researchers ask physicians to consider anti-IgLON5 disease if certain symptoms are present, as the only promising approach is…